Adeel Siddiqui, MD
Interventional Cardiology · Evansville, INNPI 1720345929
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (50.7%), food and beverage and education — rather than concentrated in one kind of arrangement. Biotronik Inc. accounts for 72.2% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2019 at $7,163 and has fallen 74.5% since, to $1,828 in 2025.
Across 181 payments — averaging $86.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotronik Inc.$11K
- Philips North America LLC$2K
- Abiomed$792
- Boston Scientific$352
- Medtronic$149
- Cardiovascular Systems Inc.$124
- plus $1K from 22 others
What the payments were for
- Travel & lodging$7,95851%
- Food & beverage$7,73549%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotronik Inc. | 88 | $11,344 |
| Philips North America LLC | 17 | $1,932 |
| Abiomed | 15 | $792 |
| Boston Scientific | 4 | $352 |
| Medtronic | 6 | $149 |
| Cardiovascular Systems Inc. | 10 | $124 |
| Heartflow, Inc. | 2 | $111 |
| Inari Medical, Inc. | 2 | $98 |
| Abbott | 1 | $94 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $80 |
| AstraZeneca | 4 | $73 |
| Angiodynamics, Inc. | 1 | $62 |
| Boehringer Ingelheim | 3 | $61 |
| Novartis | 3 | $61 |
| Penumbra, Inc. | 1 | $60 |
| Merck | 3 | $60 |
| E.r. Squibb & Sons, L.L.C. | 3 | $41 |
| Lantheus Medical Imaging, Inc. | 2 | $31 |
| AbbVie | 2 | $30 |
| Amarin Pharma, Inc. | 1 | $24 |
| Bausch Health US, LLC | 1 | $24 |
| Pfizer | 1 | $19 |
| Astellas Pharma US Inc | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
| Cardiva Medical, Inc. | 1 | $15 |
| Terumo Medical Corporation | 1 | $14 |
| Johnson & Johnson | 1 | $12 |
| Bayer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BioMonitor$1,936
- Solia$1,936
- Edora$1,724
- Acticor$1,724
- Rivacor$1,724
- (6575) Coronary Undivided$784
- PRODIGY$636
- Acticor 7 VR-T DX$485
- Edora 8 DR-T$355
- Rivacor 7 DR-T$213
- GENERAL VASCULAR ACCESS$130
- (6574) Coronary Other$119
How this compares
$15,706 in reported general payments places this provider in the 75th percentile of 170 interventional cardiology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 212 | $255,932 |
| Repatha SureclickEvolocumab | 109 | $138,932 |
| EntrestoSacubitril/Valsartan | 87 | $137,177 |
| XareltoRivaroxaban | 67 | $73,400 |
| Praluent PenAlirocumab | 44 | $29,142 |
| FarxigaDapagliflozin Propanediol | 17 | $28,680 |
| JardianceEmpagliflozin | 16 | $12,238 |
| Ranolazine ErRanolazine | 64 | $7,589 |
| Atorvastatin Calcium | 629 | $4,480 |
| Diltiazem 12hr ErDiltiazem Hcl | 13 | $4,003 |
| Metoprolol Succinate | 299 | $3,946 |
| Losartan Potassium | 232 | $1,587 |
| Midodrine Hcl | 14 | $1,399 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 135 | $1,376 |
| Amlodipine Besylate | 299 | $1,191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $19 | $255,932212 claims |
| NovartisEntresto | $61 | $137,17787 claims |
| Johnson & JohnsonXarelto | $12 | $73,40067 claims |
| AstraZenecaFarxiga | $73 | $28,68017 claims |
| Boehringer IngelheimJardiance | $61 | $12,23816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 170 interventional cardiology providers in Indiana.
Other interventional cardiology in Evansville
- Jarrod FrizzellEvansville$86K
- Anthony VoelkelEvansville$19K
- Samer AbbasEast Chicago$395K
- James HermillerIndianapolis$307K
- Woodrow CoreyIndianapolis$262K
- Muzammil MusaniFort Wayne$184K
- Dean FerreraEast Chicago$180K
- Shashidhar DivakaruniMunster$97K
- Navneet LatherNoblesville$83K
- Michael BallIndianapolis$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.